Fish Oil Protects the Heart After PCI

blood flow and blocked arteriesPercutaneous coronary intervention or PCI is a procedure that opens narrowed or blocked arteries. Some patients with severe coronary artery disease and reduced left ventricular ejection fraction may be candidates for Protected PCI, a PCI procedure using a miniature heart pump called the Impella 2.5.

A study found that people who were given omega-3 fatty acids 12 hours before their PCI procedure had lower levels of a heart biomarker after the PCI procedure. The only difference between the two groups was the addition of the 600 mg of docosahexaenoic acid (DHA) and 1200 mg of eicosapentaenoic acid (EPA) in a single fish oil pill. DHA and EPA are the primary omega-3 fatty acids needed for the body to function—especially for the immune system and the brain.

The heart biomarker studied was creatine kinase, an enzyme secreted by the heart that can indicate heart damage. Measurement of creatine kinase is routine after PCI procedures. Lower levels of creatine kinase indicate little or no heart damage after PCI.

Taking care of your heart is of utmost importance to your health. One way to protect your heart may be to eat omega-3 fatty acids or take a fish oil supplement. Previous studies have shown omega-3 fatty acids may reduce the risk of heart problems by preventing plaques from forming in arteries called atherosclerosis and improving blood flow. They have also been shown to interfere with the inflammatory response and act as anti-inflammatory agents.

This fish oil study was the first to show an effect of omega-3 fatty acids on creatine kinase. The fact that a single dose of fish oil can decrease creatine kinase suggests that the effects of omega-3 fatty acids on the immune system may be important in the development of cardiovascular disease.

Next Steps:

RIGHT-SIDE SUPPORT – INDICATION & SAFETY INFO.

Indication for Use

The Impella RP® System is indicated for providing circulatory assistance for up to 14 days in pediatric or adult patients with a body surface area ≥ 1.5 m2 who develop acute right heart failure or decompensation following left ventricular assist device implantation, myocardial infarction, heart transplant, or open-heart surgery.

Contraindications

The Impella RP is contraindicated for use with patients experiencing any of the following conditions: (1) Disorders of the pulmonary artery wall that would preclude placement or correct positioning of the Impella RP device; (2) Mechanical valves, severe valvular stenosis or valvular regurgitation of the tricuspid valve or pulmonary valve; (3) Mural thrombus of the right atrium or vena cava; (4) Anatomic conditions precluding insertion of the pump; (5) Other illnesses or therapy requirements precluding use of the pump; and (6) Presence of a vena cava filter or caval interruption device, unless there is clear access from the femoral vein to the right atrium that is large enough to accommodate a 22 Fr catheter.

Potential Adverse Events

Additionally, potential for the following risks has been found to exist with the use of the Impella RP: Arrhythmia; Atrial fibrillation; Bleeding; Cardiac tamponade; Cardiogenic shock; Death; Device Malfunction; Hemolysis; Hepatic failure; Insertion site infection; Perforation; Phlegmasia cerulea dolens (a severe form of deep venous thrombosis); Pulmonary valve insufficiency; Respiratory dysfunction; Sepsis; Thrombocytopenia; Thrombotic vascular (non-central nervous system) complication; Tricuspid valve injury; Vascular injury; Venous thrombosis; Ventricular fibrillation and/or tachycardia

The Impella RP is approved for use as a Humanitarian Device. It’s effectiveness for the above indication has not been demonstrated.

CARDIOGENIC SHOCK – INDICATION & SAFETY INFO.

Indication for Use

The Impella 2.5™, Impella CP®, Impella 5.0™ and Impella LD™ catheters, in conjunction with the Automated Impella Controller, are temporary ventricular support devices intended for short term use (≤ 4 days for the Impella 2.5 and Impella CP, and ≤ 6 days for the Impella 5.0 and LD) and indicated for the treatment of ongoing cardiogenic shock that occurs immediately (< 48 hours) following acute myocardial infarction or open heart surgery as a result of isolated left ventricular failure that is not responsive to optimal medical management and conventional treatment measures.* The intent of the Impella system therapy is to reduce ventricular work and to provide the circulatory support necessary to allow heart recovery and early assessment of residual myocardial function.
* Optimal medical management and convention treatment measures include volume loading and use of pressors and inotropes, with or without IABP.

Contraindications

In connection with the above indications, the Impella devices are contraindicated for use in patients experiencing the following conditions:
Mural thrombus in the left ventricle; Presence of a mechanical aortic valve or heart constrictive device; Aortic valve stenosis/calcification (equivalent to an orifice area of 0.6 cm2 or less); Moderate to severe aortic insufficiency (echocardiographic assessment of aortic insufficiency graded as ≥ +2); Severe peripheral arterial disease that precludes the placement of the Impella System; Significant right heart failure; Combined cardiorespiratory failure; Presence of an Atrial or Ventricular Sepal Defect (including post-infarct VSD); Left ventricular rupture; and Cardiac tamponade.

Potential Adverse Events

Additionally, potential for the following risks has been found to exist with use of the Impella devices in the above indications: Acute renal dysfunction; Aortic insufficiency; Aortic valve injury; Atrial fibrillation; Bleeding; Cardiogenic shock; Cardiac tamponade; Cardiopulmonary resuscitation; Cerebral vascular accident/Stroke; Death; Device malfunction; Failure to achieve angiographic success; Hemolysis; Hepatic failure; Insertion site infection; Limb ischemia; Myocardial infarction; Need for cardiac, thoracic or abdominal operation; Perforation; Renal failure; Repeat revascularization; Respiratory dysfunction; Sepsis; Severe hypotension; Thrombocytopenia; Thrombotic vascular (non-CNS) complication; Transient ischemic attack; Vascular injury; Ventricular arrhythmia, fibrillation or tachycardia.

PROTECTED PCI™ – INDICATION & SAFETY INFO.

Indication for Use

The Impella 2.5™ System is a temporary (≤ 6 hours) ventricular support device indicated for use during high risk percutaneous coronary interventions (PCI) performed in elective or urgent, hemodynamically stable patients with severe coronary artery disease and depressed left ventricular ejection fraction, when a heart team, including a cardiac surgeon, has determined high risk PCI is the appropriate therapeutic option. Use of the Impella 2.5 System in these patients may prevent hemodynamic instability, which can result from repeat episodes of reversible myocardial ischemia that occur during planned temporary coronary occlusions and may reduce peri- and post-procedural adverse events.

Contraindications

In connection with the above indication, the Impella 2.5™ is contraindicated for use with patients experiencing any of the following conditions:

  • Mural thrombus in the left ventricle
  • Presence of a mechanical aortic valve or heart constrictive device
  • Aortic valve stenosis/calcification (equivalent to an orifice area of 0.6 cm2 or less)
  • Moderate to severe aortic insufficiency (echocardiographic assessment graded as ≥ +2)
  • Severe peripheral arterial disease precluding placement of the Impella 2.5™ System

Potential Adverse Events

Additionally, potential for the following risks has been found to exist with use of the Impella 2.5 in the above indication: Acute renal dysfunction; Aortic insufficiency; Aortic valve injury; Atrial fibrillation; Bleeding; Cardiogenic shock; Cardiac tamponade; Cardiopulmonary resuscitation; Cerebral vascular accident/Stroke; Death; Device malfunction; Failure to achieve angiographic success; Hemolysis; Hepatic failure; Insertion site infection; Limb ischemia; Myocardial infarction; Need for cardiac, thoracic or abdominal operation; Perforation; Renal failure; Repeat revascularization; Respiratory dysfunction; Sepsis; Severe hypotension; Thrombocytopenia; Thrombotic vascular (non-CNS) complication; Transient ischemic attack; Vascular injury; Ventricular arrhythmia, fibrillation or tachycardia.